Capital Advisors Ltd’s Passage Bio PASG Stock Holding History

Capital Advisors Ltd’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-9	Closed	–	–	1443
2022 Q2	$0	Buy	9 +8	+800%	+$374	﹤0.01%	1232
2022 Q1	$0	Buy	+1	New	+$82	﹤0.01%	1131

Other funds holding PASG

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Capital Advisors Ltd's PASG Position: Q3 2022 in Review

Capital Advisors Ltd sold out of Passage Bio (PASG) in Q3 2022, closing a stake of 9 shares.

Capital Advisors Ltd first reported a position in PASG in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 75 funds tracked by Wall St. Rank hold PASG as of Q3 2022.

Capital Advisors Ltd reported no remaining Passage Bio position as of Q3 2022 after selling out during the quarter.
Capital Advisors Ltd sold 9 Passage Bio shares in Q3 2022.
Capital Advisors Ltd first reported a position in Passage Bio in Q1 2022 and held it in 2 quarters.
Capital Advisors Ltd's Passage Bio position peaked at $0 in Q2 2022.
75 funds tracked by Wall St. Rank held Passage Bio as of Q3 2022.

Based on Capital Advisors Ltd's 13F filing for Q3 2022, filed 9 Nov 2022.